Your browser doesn't support javascript.
loading
Chinese herbal compound for multidrug-resistant or extensively drug-resistant bacterial pneumonia: a meta-analysis and trial sequential analysis with association rule mining to identify core herb combinations.
Zhao, Shuman; Geng, Yanting; Shi, Jiaheng; Qian, Jing; Yang, Yebeilei; Dai, Dan; Yan, Zimin; Qi, Wensheng; Yu, Daxing; Zhao, Xin.
Afiliação
  • Zhao S; Guang'Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Geng Y; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Shi J; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Qian J; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Yang Y; Guang'Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Dai D; Department of Dermatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Yan Z; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Qi W; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Yu D; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Zhao X; Department of Emergency, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol ; 14: 1282538, 2023.
Article em En | MEDLINE | ID: mdl-38174222
ABSTRACT

Purpose:

Antibiotic-resistant bacterial pneumonia poses a significant therapeutic challenge. In China, Chinese herbal compound (CHC) is commonly used to treat bacterial pneumonia. We aimed to evaluate the efficacy and safety of CHC and identify core herb combinations for the treatment of multidrug-resistant or extensively drug-resistant bacterial pneumonia.

Methods:

Stata 16 and TSA 0.9.5.10 beta software were used for meta-analysis and trial sequential analysis (TSA), respectively. Exploring the sources of heterogeneity through meta-regression and subgroup analysis.

Results:

Thirty-eight studies involving 2890 patients were included in the analyses. Meta-analysis indicated that CHC combined with antibiotics improved the response rate (RR = 1.24; 95% CI 1.19-1.28; p < 0.0001) and microbiological eradication (RR = 1.41; 95% CI 1.27-1.57; p < 0.0001), lowered the white blood cell count (MD = -2.09; 95% CI -2.65 to -1.53; p < 0.0001), procalcitonin levels (MD = -0.49; 95% CI -0.59 to -0.40; p < 0.0001), C-reactive protein levels (MD = -11.80; 95% CI -15.22 to -8.39; p < 0.0001), Clinical Pulmonary Infection Scores (CPIS) (MD = -1.97; 95% CI -2.68 to -1.26; p < 0.0001), and Acute Physiology and Chronic Health Evaluation (APACHE)-II score (MD = -4.08; 95% CI -5.16 to -3.00; p < 0.0001), shortened the length of hospitalization (MD = -4.79; 95% CI -6.18 to -3.40; p < 0.0001), and reduced the number of adverse events. TSA indicated that the response rate and microbiological eradication results were robust. Moreover, Scutellaria baicalensis Georgi, Fritillaria thunbergii Miq, Lonicera japonica Thunb, and Glycyrrhiza uralensis Fisch were identified as core CHC prescription herbs.

Conclusion:

Compared with antibiotic treatment, CHC + antibiotic treatment was superior in improving response rate, microbiological eradication, inflammatory response, CPIS, and APACHE-II score and shortening the length of hospitalization. Association rule analysis identified four core herbs as promising candidates for treating antibiotic-resistant bacterial pneumonia. However, large-scale clinical studies are still required. Systematic Review Registration https//www.crd.york.ac.uk/prospero/, identifier CRD42023410587.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article